What′s known
============

The results of clinical studies have shown that implementation of intervention programmes for the management of type 2 diabetes mellitus has a positive impact in quality of care. However, limited data are currently available from primary care settings.

What′s new
==========

The present study describes the impact of the Group for the Study of Diabetes in Primary Care intervention programme on type 2 diabetes mellitus quality of care in primary care settings in Spain by analysis of the trend of quality indicators.

Introduction
============

The benefits of controlling type 2 diabetes mellitus (DM) and the associated cardiovascular risk factors are well established and reflected in the current clinical practice guidelines ([@b1]--[@b4]). However, the results of several cross-sectional studies have highlighted the difficulties in achieving the goals as well as the full implementation of the clinical recommendations ([@b5]--[@b9]). The results of consecutive cross-sectional observational studies have shown some positive trends on both process indicators and degree of disease control ([@b10]--[@b17]).

Moreover, the results of several clinical trials conducted to evaluate different quality improvement programmes at both primary and secondary care centres have shown significant improvements in both process and intermediate outcome indicators (degree of glycemic control and other risk factors) with some impact on final outcome indicators like hospital admissions and health-related costs ([@b18]--[@b20]). The feedback of the indicators′ results to the health providers is considered the basis for any quality improvement intervention ([@b21]--[@b23]). In Spain, there is limited information published in this regard, mainly from cross-sectional studies ([@b5]--[@b9],[@b17]).

In 1992, the Group for the Study of Diabetes in Primary Care (GEDAPS) was founded by the Catalan Society of Community and Family Medicine to implement the aims of the Saint Vincent Declaration ([@b1]). In 1993, the group published the first edition of the 'Guidelines for Diabetes Management in Primary Health Care in Spain' that included both clinical and organisational recommendations and also defined a set of quality care indicators. The guidelines were updated in the following years (1995, 1998, 2000 and 2004) ([@b2]). In parallel, the group developed the GEDAPS continuous quality improvement (GCQI) computer programme to facilitate clinical audits. The programme constructed automatically process and outcome indicators based on the data recorded by the participant centres from random samples of patients′ medical records. In 1996, the programme was expanded to other Spanish regions ([@b17]). The GCQI programme was mainly based on the feedback of the results of the clinical indicators to the participating centres to promote interventions to improve quality of care.

In 1993, the first evaluation of quality of care of type 2 DM in primary care settings took place in Catalonia. The evaluation was repeated in 1995, 1998, 2000, 2002 and 2007. At the same time, as part of the intervention, a series of workshops and seminars were launched to publicise and implement the GEDAPS guidelines as well as the recommendations to improve early detection of the disease, treatment, management of diabetes complications and specific workshops to analyse quality indicators and propose local interventions to improve patient′s quality of care.

The aim of the present study was to describe the impact of the GEDAPS intervention programme on type 2 DM quality of care in primary care settings, by analysing the trend of quality indicators collected in assessments that took place between 1993 and 2007 in Catalonia, Spain.

Research design and methods
===========================

Study design
------------

The GCQI programme gathered information from primary care centres (PCC) on process and outcomes indicators in a sample of their patients. To promote their participation, letters by ordinary mail and electronic mails (years 2000--2002) were sent to all PCC in Catalonia. The planned 2005 survey was not conducted because the medical records were being computerised during the previous years. During the last evaluation (2007), several investigator meetings around the territory were conducted to encourage participation in the study, regardless of their participation in the previous evaluations and to present changes in data entry using a webpage (<http://www.redgdps.org/>).

Health providers entered patient data using the GCQI computer programme that immediately provided the results of a set of disease-specific processes and outcomes indicators. Data were subsequently sent by disk (1993--2000), electronic mail (2002) or introduced directly in the redgedaps.org web (only in 2007). The GCQI computerised programme was specifically designed to perform periodic evaluations (audits) in primary care centres. The programme was based in two principles: data collection from each participant centre (each participant centre had a nurse or physician responsible of the survey) and subsequent data feedback to the centres. Thus, each centre was able to compare their data during subsequent assessments (internal comparison) and with data from other centres (external comparison). The gold standard for each indicator in each evaluation was the overall result of all the participating centres. Each centre then compared their own results with the global results (gold standard) to find differences that required to be improved.

Health providers were instructed to obtain a random sample from the medical records of type 2 DM patients with a follow-up greater than 6 months since diagnosis. A total sample of five patients multiplied for the number of basic care units (physician/nurse), with a minimum of 30 patients per centre, was required. A preselection of medical records with an additional 20% was performed. In those cases that did not fulfil the inclusion criteria the medical record was replaced by the next one of the same gender. Exclusion criteria included: type 1 DM; follow-up exclusively by an endocrinologist and short life expectancy (terminal patients or those that received home care).

Because of the retrospective nature of the study, based only on clinical records, patients were not required to give written informed consent. To assure anonymity, data were collected and recorded using two different files: one included demographic variables and the other one included clinical variables linked by a consecutive record number. The study design and the GCQI programme were presented and approved by the Consell Assessor de la Diabetis (Advisory Board on Diabetes) of the Health Department of the Autonomous Government in Catalunya that behaved as Institutional Review Board.

Data were collected from paper medical records from 1997 to 2002 and from electronic records in 2007. Data about the characteristic of the centre (rural or urban), number of doctors and nurses team (basic care units), total population and prevalence of diabetes were fulfilled by the professional responsible of the evaluation.

GCQI programme interventions
----------------------------

The GCQI programme was mainly based on the feedback of the results of clinical indicators that were sent after each evaluation to the participating centres to promote interventions to improve quality of care. On the other hand, as part of the intervention programme, 55 courses, seminars and workshops were conducted during the study period to disseminate the GEDAPS Guidelines and its recommendations, and a total of 2041 health professionals (physicians and nurses) attended. The main aim of the courses and workshops was to encourage the global management of the disease, not only to improve glycemic control but also to promote the proper management of other cardiovascular risk factors as well as the performance of annual activities leading to early detection and treatment of diabetes complications. In relation to the nurses clinical activities, a special emphasis was put on reviewing the educational interventions, annual screening activities and the degree of disease control in each patient, and not be limited to explain diet or performing clinic measurements, that is the traditional role of nurses in our country.

Moreover, after the evaluations that took place in 1995 and 1998, nine decentralised workshops with the participation of 289 health professionals from 151 primary care teams (43% of the primary care centres of Catalonia), were conducted to analyse the results and identify healthcare difficulties to propose local corrective interventions.

Variables
---------

### Demographic and clinical characteristics

Age; gender; weight; height; body mass index (BMI), blood pressure; glycated haemoglobin (HbA~1c~); total cholesterol and HDL-cholesterol; year of diabetes diagnosis; number of doctor or nurse visits, number of educational interventions recorded per year; antidiabetic treatment and smoking status.

### Process and outcome indicators of quality of care

The following indicators, that have been previously described elsewhere, were studied ([@b17]): Process indicators: (i) related to the organisation: No visit related to diabetes recorded; less than three nursing visits; less than three educational interventions of different topic (whatever the number of visits required to perform the intervention for each topic); practice of self-monitoring blood glucose; (ii) laboratory measurements: at least one HbA~1c~ determination; two or more HbA~1c~ determinations; at least one total cholesterol determination; at least one HDL-cholesterol determination; at least one microalbuminuria screening determination; (iii) physical examinations: weight measurements (three or more times a year); funduscopy done by an ophthalmologist; foot examination; Outcome indicators: (i) intermediate outcomes: Good glycemic control (HbA~1c~ ≤ 7% or 57 mmol/mol); acceptable glycemic control (HbA~1c~ ≤ 8% or 68 mmol/mol); very poor glycemic control (HbA~1c~ \> 10% or 89 mmol/mol); HDL-Cholesterol \> 40 mg/dl (1.03 mmol/l); total cholesterol ≤ 250 mg/dl(6.47 mmol/l) (acceptable control); total cholesterol ≤ 200 mg/dl (5.17 mmol/l) (strict control); BMI \< 30 kg/m^2^; BP ≤ 140/90 mmHg (acceptable control); BP ≤ 130/80 mmHg (strict control); active smoking; (ii) final outcomes: diabetic foot (ulcers + amputations); diabetic foot ulcers; amputations of lower limbs; nephropathy (microalbuminuria or macroalbuminuria); retinopathy; amaurosis; coronary artery disease (including angina); stroke (including transient ischaemic attack); hospital admissions because of amputation, hypoglycemia or any other reason, but with plasma blood glucose \> 500 mg/dl(27.28 mmol/l).

Statistical considerations
--------------------------

Continuous variables were described using the mean and standard deviation. Categorical variables are described as percentage with the confidence interval of 95% (95% CI). The SPSS.11 statistical program was used for all statistical analyses.

Results
=======

During the study period (1993--2007) 55 seminars were conducted and a total of 2041 health professionals (physicians and nurses) from 1084 centres attended. [Table 1](#tbl1){ref-type="table"} summarises the characteristics of the primary care participant centres. The PCC covered one-third of the population of Catalonia (7,364,068 individuals in 2007). The number of participant centres increased over time, from 1993 to 2002, with a decline during the last evaluation (2007). More than half of the centres were urban, reaching 67.3% in 2007. The prevalence of type 2 DM increased over time, from 3.3% in 1993 to 5.4% in 2007 (relative increase of 63%).

###### 

Participant centres and patient characteristics in each evaluation[\*](#tf1-1){ref-type="table-fn"}

                                                          1993                1995                1998                2000                2002                2007
  ------------------------------------------------------- ------------------- ------------------- ------------------- ------------------- ------------------- -------------------
  **Characteristics of participant centres**                                                                                                                  
   Number of participating centres                        57                  75                  75                  78                  96                  52
   Urban centres (%)                                      54.4 (41.1--66.9)   56 (44.8--67.2)     56.6 (45.4--67.8)   52.6 (41.5--63.7)   57.3 (47.4--67.2)   67.3 (54.5--80.0)
   Number of basic care units (physician + nurse)         433                 565                 609                 680                 846                 637
   Total assigned population                              954,126             1,251,689           1,367,639           1,474,242           1,888,593           1,126,532
   Assigned population over 14 years old                  694,450             982,567             1,058,903           1,203,310           1,541,618           938,429
   Number of patients with diabetes over 14 years         22,663              38,697              51,776              63,831              83,859              55,350
   Prevalence of diabetes in patients over 14 years (%)   3.3 (3.0--3.5)      4.0 (3.8--4.2)      4.9 (4.7--5.1)      5.3 (5.1--5.5)      5.4 (5.2--5.5)      5.4 (5.2--5.6)
  **Patients\' characteristics**                                                                                                                              
   Number of participants                                 2239                3532                4217                4564                5819                3130
   Gender (% female)                                      56.6 (54.5--58.6)   54.5 (52.9--56.1)   52.9 (51.4--54.4)   52.1 (50.6--53.5)   51.8 (50.5--53.1)   48.5 (46.7--50.2)
   Age (years), mean (SD)                                 65.2 (10.2)         66.3 (10.3)         67.2 (10.6)         67.1 (10.8)         67.3 (10.9)         68 (11.7)
   \> 65 years old patients (%)                           50.9 (48.8--53.0)   55.4 (53.8--57.0)   59.6 (58.1--68.1)   60.0 (58.6--61.4)   60.5 (59.2--61.8)   60.2 (58.5--61.9)
   Diabetes duration (years), mean (SD)                   7.5 (7.1)           7.8 (7.5)           8.2 (7.1)           7.6 (6.8)           8.0 (6.9)           7 (5.6)
   Prevalence of obesity (BMI ≥ 30 kg/m^2^) (%)           37.0 (35.0--39.0)   37.0 (35.4--38.6)   39.2 (37.7--40.7)   40.5 (39.1--41.2)   42.6 (41.3--43.9)   50.3 (48.5--52.0)
   HbA~1c~ (%), mean (SD)                                 7.7 (1.9)           7.6 (1.6)           7.1 (1.6)           7.0 (1.7)           7.1 (1.4)           6.8 (1.4)
   Physician visits related to diabetes, mean (SD)        3.7 (3.4)           2.9 (3.7)           2.7 (2.7)           2.8 (2.7)           2.6 (2.4)           4.1 (4.0)
   Nurse visits related to diabetes, mean (SD)            5.1 (3.7)           5.1 (4.2)           4.6 (3.3)           4.2 (3.2)           3.6 (2.6)           4.8 (4.1)
  **Antidiabetic treatment (%)**                                                                                                                              
   Diet and exercise alone                                25.7 (23.9--27.5)   27.7 (26.2--29.2)   29.4 (28.0--30.8)   27.9 (26.6--29.2)   25.4 (24.3--26.5)   22.3 (20.8--23.7)
   Oral antidiabetic drugs                                52.2 (50.1--54.3)   50.0 (48.3--51.2)   49.9 (48.4--51.4)   51.7 (50.2--53.1)   54.6 (53.3--55.9)   60.5 (58.8--62.2)
   Insulin (monotherapy)                                  20.0 (18.3--21.7)   20.2 (19.9--21.5)   17.8 (16.6--18.9)   15.2 (14.2--16.2)   12.3 (11.5--13.1)   7.3 (6.4--8.2)
   Insulin + oral antidiabetic drug                       2.1 (1.5--2.7)      2.0 (1.5--2.5)      2.8 (2.3--3.3)      5.2 (4.6--5.8)      7.6 (6.9--8.3)      10.0 (8.9--11.0)

Data expressed as absolute numbers, means (standard deviation, SD) or percentages (95% confident interval)

Patients′ characteristics
-------------------------

The clinical records of 23,501 patients were evaluated. [Table 1](#tbl1){ref-type="table"} summarises the characteristics of patients in each evaluation. Mean age increased from 65.2 years (SD: 10.2; range: 30--93) in 1993 to 67 years (SD: 10.9; range: 31--99) in 2007, with a significant progressive increase in the percentage of patients \> 65 years old (50.9% vs. 60.2%). Other significant differences found between 1993 and 2007 evaluation included: lower number of female patients (56.6% vs. 48.5%); higher prevalence of obesity (37% vs. 50%); shorter time of diabetes duration (7.5 years vs. 7 years) and lower HbA~1c~ concentration (7.7% or 64 mmol/mol vs. 6.8% or 55 mmol/mol).

Throughout the study, more than half of the participants received oral antidiabetic treatment, whereas approximately 20% of the patients received insulin (alone or in combination therapy). Among this latter patient population, the percentage that received combined treatment (insulin + oral antidiabetics) increased significantly over time (2.1% vs. 10%) ([Table 1](#tbl1){ref-type="table"}).

Process indicators
------------------

### Related to organisation

Throughout the study the number of patients that did not have any diabetes-related visit recorded significantly decreased (5.1% in 1993 vs. 2% in 2007), with an increase in the percentage of patients that visited the nurse more than three times per year (27.3% in 1993 vs. 31.5% in 2007). Doctors and nurses visits tend to decrease progressively, but increased in 2007. Likewise, a significant decrease was observed in the percentage of patients receiving less than three different annual educational interventions (74.6% in 1993 vs. 58.3% in 2007) ([Table 2](#tbl2){ref-type="table"}).

###### 

Evolution of process and outcome indicators[\*](#tf2-1){ref-type="table-fn"}

                                                                                              1993 (*n* = 2239)   1995 (*n* = 3532)   1998 (*n* = 4217)   2000 (*n* = 4567)   2002 (*n* = 5819)   2007 (*n* = 3130)   Difference
  ------------------------------------------------------------------------------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------------
  **Process indicators**                                                                                                                                                                                              
   Related to the organisation                                                                                                                                                                                        
    No diabetes-related visit recorded                                                        5.1 (4.2--6.0)      3.0 (2.4--3.6)      1.7 (1.3--2.1)      2.1 (1.7--2.5)      2.2 (1.8--2.6)      2.0 (1.5--2.5)      −3.1 (−4.1 to −2.0)
    Less than three nursing visits                                                            27.3 (25.5--29.2)   27.6 (26.1--29.1)   28.4 (27.0--29.8)   32.8 (31.4--34.2)   35.9 (34.7--37.1)   31.5 (29.9--33.1)   +4.2 (1.8 to 6.7)
    Less than three educational interventions                                                 74.6 (72.8--76.4)   56.3 (54.7--57.9)   61.2 (59.7--62.7)   67.2 (65.8--68.6)   64.6 (63.4--65.8)   58.3 (56.6--60.0)   −16.3 (−18.8 to −13.8)
   Control parameters                                                                                                                                                                                                 
    At least one blood pressure measurement                                                   94.5 (93.6--95.4)   93.0 (92.2--93.8)   93.9 (93.2--94.6)   92 (91.2--92.8)     92.2 (91.5--92.9)   92.3 (91.4--93.2)   −2.2 (−3.5 to −0.9)
    At least one HbA~1c~ measurement                                                          51.7 (49.6--53.4)   70.2 (68.7--71.7)   77.6 (76.3--78.9)   82.8 (81.7--83.9)   85.3 (84.4--86.2)   88.9 (87.8--90.0)   +37.2 (34.9 to 39.5)
    Two or more HbA~1c~ measurements                                                          30.0 (28.1--31.9)   41.1 (39.5--42.7)   40.6 (39.1--42.1)   42.2 (40.8--43.6)   55.5 (54.2--56.8)   40.4 (38.7--42.1)   +10.4 (7.8 to13.0)
    At least one total cholesterol measurement                                                75.9 (74.1--77.7)   80.5 (79.2--81.8)   83.1 (82.0--84.2)   84.4 (83.4--85.5)   86.5 (85.6--87.4)   90.9 (89.9--91.9)   +15.0 (13.0 to 17.1)
    Weight control (three or more times a year)                                               44.9 (42.8--47.0)   32.7 (31.2--34.3)   31.3 (29.9--32.7)   33.5 (32.1--34.9)   40.5 (39.2--41.8)   40.2 (38.5--41.9)   −4.7 (−7.4 to −2.0)
   Screening for complications                                                                                                                                                                                        
    Funduscopy performed by an ophthalmologist                                                52.2 (50.1--54.3)   48.4 (46.8--50.1)   52.6 (51.1--54.1)   52.2 (50.8--53.7)   54.3 (53.0--55.6)   49.0 (47.3--50.8)   −3.2 (−5.9 to −0.5)
    Foot examination                                                                          48.9 (46.8--51.0)   58.3 (56.7--59.9)   54.3 (52.8--55.8)   54.1 (52.7--55.6)   56.6 (55.3--57.9)   64.2 (62.5--65.9)   +15.3 (12.6--17.9)
    Determination of microalbuminuria                                                         33.9 (31.9--35.9)   49.0 (47.4--50.7)   62.5 (61.0--64.0)   68.7 (67.4--70.0)   72.8 (71.7--73.9)   59.4 (57.7--61.1)   +25.5 (23.6--27.4)
  **Outcome indicators**                                                                                                                                                                                              
   Intermediate outcomes                                                                                                                                                                                              
    Good glycemic control (HbA~1c~ ≤ 7%) (57 mmol/mol)                                        41.5 (39.5--43.5)   42.2 (40.6--43.8)   54.7 (53.2--56.2)   58.7 (57.3--60.1)   56.5 (55.2--57.8)   64.2 (62.5--65.9)   +22.7 (20.1 to 25.3)
    Acceptable glycemic control (HbA~1c~ ≤ 8%) (68 mmol/mol)                                  62.6 (60.6--64.6)   65.4 (63.8--67.0)   74.0 (72.7--75.3)   77.6 (76.4--78.8)   78.6 (77.6--79.7)   83.3 (82.0--84.6)   +20.7 (18.3 to 23.1)
    Very poor glycemic control (HbA~1c~ ≥ 10%) (89 mmol/mol)                                  13.4 (12.0--14.8)   10.4 (9.4--11.4)    5.7 (5.0--6.4)      5.7 (5.0--6.4)      4.6 (4.1--5.1)      4.2 (3.5--4.9)      −9.2 (−10.8 to −7.6)
    HDL-cholesterol \> 40 mg/dl (1.03 mmol/l)                                                 74.7 (72.9--76.5)   72.2 (70.7--73.7)   77.2 (75.9--78.5)   78.0 (76.8--79.2)   77.6 (76.5--78.7)   83.0 (81.7--84.3)   +8.3 (6.5 to10.5)
    Total cholesterol ≤ 250 mg/dl (6.47 mmol/l)                                               73.1 (71.3--74.9)   77.0 (75.6--78.4)   77.4 (76.1--78.7)   85.8 (84.8--86.8)   87.0 (86.1--87.9)   92.4 (91.5--93.3)   +19.3 (17.2 to 21.3)
    Total cholesterol ≤ 200 mg/dl (5.17 mmol/l).                                              25.5 (23.7--27.3)   29.4 (27.9--30.9)   31.9 (30.5--33.3)   41.3 (39.9--42.7)   46.3 (45.0--47.6)   65.6 (63.9--67.3)   \+ 40.1 (37.6 to 42.5)
    Body mass index \< 30 kg/m^2^                                                             63.0 (61.0--65.0)   63.0 (61.4--64.6)   60.8 (59.3--62.3)   56.9 (55.5--58.3)   57.4 (56.1--58.7)   49.7 (48.0--51.5)   −13.3 (−16.0 to −10.6)
    BP ≤ 140/90 mmHg                                                                          45.4 (43.3--47.5)   47.4 (45.8--49.1)   50.1 (48.6--51.6)   54.9 (53.5--56.3)   58.8 (57.5--60.1)   66.1 (64.4--67,8)   +20.7 (18.0--23.3)
    BP ≤ 130/80 mmHg                                                                          22.0 (20,3--23,7)   23.3 (21.9--24.7)   24.6 (23.3--25.9)   26.8 (25.5--28.1)   30.5 (29.3--31.7)   35.0 (33.3--36.7)   +13 (10.6--15.4)
    Active smoking                                                                            13.4 (12.0--14.8)   14.3 (13.2--15.5)   15.0 (13.9--16.1)   14.4 (13.4--15.4)   15.4 (14.5--16.3)   13.6 (12.4--14.8)   −0.2 (−2.1 to 1.6)
   Final outcomes (prevalence on complications)                                                                                                                                                                       
    Diabetic foot (ulcers plus amputations)                                                   9.5 (8.3--10.7)     6.0 (5.2--6.8)      4.2 (3.6--4.8)      3.5 (3.0--4.0)      3.0 (2.6--3.4)      3.2 (2.6--3.8)      −6.3 (−7.7 to −5.0)
    Diabetic foot ulcers                                                                      7.6 (6.5--8.7)      5.4 (4.7--6.2)      3.4 (2.8--4.0)      2.7 (2.2--3.2)      2.3 (1.9--2.7)      2.6 (2.0--3.2)      −5 (−6.8 to −3.2)
    Amputations of lower limbs                                                                1.9 (1.3--2.4)      1.6 (1.2--2.0)      0.8 (0.5--1.1)      0.8 (0.5--1,1)      0.7 (0.5--0.9)      0.6 (0,3--0,9)      −1.3 (−1.9 to −0.7)
    Nephropathy (micro or macroalbuminuria)                                                   7.1 (6.0--8.2)      6.7 (5.9--7.5)      7.1 (6.3--7.9)      7.0 (6.3--7.7)      7.1 (6.4--7.8)      9.9 (8.8--11.0)     +2.8 (1.3 to 4.3)
    Retinopathy                                                                               18.8 (17.2--20.4)   14.5 (13.3--15.7)   13.5 (12.5--14.5)   10.3 (9.4--11.2)    9.8 (9.0--10.6)     8.6 (7.6--9.6)      −10.2 (−12.1 to −8.3)
    Amaurosis                                                                                 2.7 (2.0--3.4)      3.3 (2.7--3.9)      3.1 (2.6--3.6)      2.1 (1.7--2.5)      2.1 (1.7--2.5)      0.3 (0.1--0.5)      −2.4 (−3.1 to 1.7)
    Coronary artery disease                                                                   12.9 (11.5--14.3)   12.0 (10.9--13.1)   12.5 (11.5--13.5)   11.2 (10.3--12.1)   12.5 (11.7--13.4)   11.3 (10.2--12.4)   −1.6 (−3.4 to 0.2)
    Stroke                                                                                    6.8 (5.8--7.8)      6.8 (6.0--7.6)      6.6 (5.9--7.4)      5.9 (5.2--6.6)      5.7 (5.1--6.3)      6.3 (5.5--7.2)      −0.5 (−1.8 to 0.9)
    Hospital admission for amputation, hypoglycemia or glycemia \> 500 mg/dl (27.76 mmol/l)   3.8 (3.0--4.6)      4.9 (4.2--5.6)      6.3 (5.6--7.0)      7.6 (6.8--8.4)      6.8 (6.2--7.5)      6.8 (5.9--7.7)      +3.0 (1.8 to 4.2)

All results are expressed as percentage with 95% confident interval related to the population of the year evaluated.

### Control parameters

A significant increase in the number of annual analytical determinations of HbA~1c~ (51.7% in 1993 vs. 88.9% in 2007) and total cholesterol (75.9% vs. 90.0%) was observed ([Table 2](#tbl2){ref-type="table"} and [Figure 1A](#fig01){ref-type="fig"}).

![(A) Process indicators: HbA~1c~, total cholesterol and blood pressure. Percentage of patients with at least one annual measurement. (B) Process indicators: complications screening. Percentage of patients with annual foot exploration, fundus examination and albuminuria screening. (C) Intermediate outcome indicators: percentage of patients with acceptable control of HbA~1c~, total cholesterol and blood pressure. Equivalencies: 250mg/dl = 6.47 mmol/l; 8% = 68 mmol/mol. (D) Intermediate outcome indicators: percentage of patients with strict control of HbA~1c~, total cholesterol and blood pressure. Equivalencies: 200mg/dl = 5.17 mmol/l; 7% = 57 mmol/mol](ijcp0066-0289-f1){#fig01}

### Complications screening

As for regular checkups, there has been improvement in the percentage of patients that have been tested for microalbuminuria (33.9 in 1993 vs. 72.8% in 2002), although a fall was observed in 2007 (59.4%). The funduscopy examination initially improved, but then remained stable with some downward trend in the last assessment (52.2% vs. 49%). In addition, foot exploration increased significantly throughout the study (48.9% vs. 64.2%) ([Table 2](#tbl2){ref-type="table"}).

Outcome indicators
------------------

### Trends in intermediate outcome indicators

Throughout the study significant improvements were observed in glycemic control, increasing the percentage of patients with HbA~1c~ ≤ 8% or 68 mmol/mol (from 62.6% to 92% and reducing the number of patients with very poor glycemic control (HbA~1c~ ≥ 10% or 89 mmol/mol) from 13.4% to 4.2%. In addition, a significant increase in the percentages of patients with acceptable control of total cholesterol (≤ 250 mg/dl-6.47 mmol/l), (from 73% to 92.4%) and blood pressure control (≤ 140/90 mmHg) (from 45.4% to 57.1%) was also noted ([Table 2](#tbl2){ref-type="table"} and [Figure 1B](#fig01){ref-type="fig"}). Using more strict control criteria, HbA~1c~ ≤ 7% or 57 mmol/mol increased from 41.5% to 64.2%, total cholesterol (≤ 200 mg/dl-5.17 mmol/l) from 25.5% to 65.6% and blood pressure (≤ 130/80 mmHg) from 22% to 35% ([Table 1](#tbl1){ref-type="table"} and [Figure 1C](#fig01){ref-type="fig"}). In contrast, no change in the percentage of active smokers (13.4% and 13.6%) and an increase in obese patients (BMI ≥ 30) (from 37% to 50%) were noted ([Table 2](#tbl2){ref-type="table"}).

### Trends in final outcome indicators

There has been a significant decrease in the prevalence of retinopathy (from 19.8% to 8.6%) and a slight increase in the prevalence of nephropathy (micro or microalbuminuria, from 7.1% to 9.9%) ([Table 2](#tbl2){ref-type="table"}). Prevalence of diabetic foot ulcers (from 7.6% to 2.6%) and amputation (from 1.9% to 0.6%) has also significantly decreased. In contrast, reductions in macrovascular complications have been much poorer: ischaemic heart disease (12.9% vs. 11.3%) and stroke (6.8% vs. 6.3%). The number of patients that required hospital admission because of hyperglycemic decompensation increased significantly throughout the study (from 3.8% to 6.8%).

Discussion
==========

The present study analyses the evolution of type 2 DM management in primary care settings in Catalonia. During the study period, a significant increase in the prevalence of DM2 and obesity was observed, probably related to the epidemic increase in the prevalence of obesity in the western countries during the last decades. However, there were no important changes in the mean age and sex distribution, duration of the disease and steps of treatment.

The significant improvements observed in some of the process indicators, in particular glycemic control, blood pressure and cholesterol, may have contributed to the reduction of key chronic complications associated with the disease, such as retinopathy and diabetic foot. These improvements meet the expectations of reducing the percentage of complications included among the goals of the Declaration of Saint Vincent ([@b1]).

The analysis of the evolution of process indicators highlight the improvement of laboratory measurements (HbA~1c~, cholesterol, and albuminuria) that are essential to assess the need or the effect of treatments as well as patient risk. However, the limited improvement observed in foot and funduscopy examinations noted in the study should be carefully analysed because such explorations are essential to early detection.

The improvements in type 2 DM process indicators observed in the present study are comparable with the trends described in other studies. Thus, the results of a population-based study that compared the results of successive cross-sections in 1988 (1024 patients) and 2006 (13,078 patients) to assess changes in quality of type 2 DM care in United States by using standardised measures showed a significant improvement in HbA~1c~ (from 34% to 51%), funduscopy (from 63.2% to 67.7%) and foot examination (from 65.4% to 68.3%) ([@b10]). Similarly, in another study conducted among Medicare beneficiaries with diabetes between 1992 (150,000 patients) and 2001 (230,000 patients) the number of HbA~1c~ and funduscopy examinations significantly increased (from 31% to 76% and from 49% to 57% respectively) ([@b11]). Other studies conducted in the UK, Israel, Netherlands, Sweden and U.S. also show improvements in the indicator trends although such studies had limitations regarding the number of patients analysed (reduced sample sizes) and length of follow-ups (\< 5 years) ([@b13]--[@b16]). The effect of pay-for performance on the quality of primary care has been recently evaluated in England ([@b16]).

The improvement in all composite measures of quality (80% and 90% in the determination of HbA~1c~, blood pressure and lipids) confirmed the benefits of such strategy. In addition, between 1998 and 2007 foot exploration increased from 57.4% to 91.5% and funduscopy examination from 69.4% to 81.1%. Such increases were significantly higher than those observed in our study.

With regard to intermediate outcomes in the British intervention, the proportion of patients who achieved the target A~1C~ value (≤ 7.5%) increased from 59.1% to 66.7%, the proportion that achieved the target BP (≤ 145/85 mmHg) increased from 70.9% to 80.2%, and finally, the proportion that achieved the target TC value (≤ 5 mmol/l) increased from 72.6% to 83.6%^16^. Although the differences in the targets between the British intervention and our study does not allow a head-to-head comparison of the results; nevertheless both showed a similar positive trend.

In the Spanish health system the role of nurses in the management of type 2 DM has increased steadily over the past 20 years. Nurses often perform, in addition to educational endeavours, foot examination as well as analytical determinations and funduscopy examination requests. Therefore, it is important to highlight their potential role in the improvements obtained in the present study. In fact, different experiences in the U.S. have shown that nurses can achieve equal or better results compared with physicians, especially when are provided with software tools to help decision-making ([@b24]--[@b26]).

Concerning the changes observed in the present study with regard to intermediate and final outcome indicators should not be attributable solely to the GCQI programme, but instead, are a reflection of the progressive changes in type 2 DM disease management experienced by our health system. This time trend of improvement in diabetic control has also been observed in prior cross-sectional studies conducted in US ([@b10],[@b11]) and Europe ([@b12],[@b14],[@b15]). Moreover, an improvement in outcome indicators has also been described in a prior study conducted in the US. Thus, medical records from Medicare patients, analysed between 1992 (150,000 patients) and 2001 (230,000 patients) showed a reduction of foot amputations in 22% associated with a 4% increase in the prevalence of retinopathy ([@b11]).

The significant reduction observed in diabetic foot lesions and retinopathy may reflect the educational and prevention interventions conducted by the health professionals. However, these improvements may also be due in part to the intensification of type 2 DM diagnosis screenings, the lowering of the glycemic cut-offs in the 1997 diagnostic criteria from 140 to 126 mg/dl (7.77--7 mmol/l) and the improvement in diagnosis registration. Such changes have led to the inclusion of patients in earlier stages of the disease and therefore increasing the percentage of patients belonging to the less severe category. This could explain the fact that the HbA~1c~ percentage and the prevalence of microvascular complications or time since diagnosis have decreased in recent assessments. However, the prevalence of heart disease and stroke has not decreased and this could be because of the similar mean age of patients in each evaluation and the limited impact of glycemic control on macrovascular complications ([@b27]). Finally, one unexpected result is the slight increase observed in hospital admissions that could be explained by an improvement in clinical records, but we cannot exclude an increase in severe hypoglycemia because of the intensification of pharmacological treatment. As the indicator only includes the number of admissions, but not the reason, it is impossible to discard the possible effect of the feedback of the results on glycemic control that could lead to an overtreatment of some patients. However, as the results about glycemic control are from the whole centre and not at individual level (nor doctor neither patient) it seems improbably that the feedback could affect directly their patients. At the same time, the threshold for the intensification of treatment in our GEDAPS guidelines and in the pay-for-performance of our institution was 8% and this relatively soft threshold could protect our patients from overtreatment. The registration of the number of severe hypoglycemic episodes would be a very interesting indicator to add to future audits.

The main limitations of this study include the design of the study, based on quality interventions rather than epidemiological or investigational purposes, and the lack of a control group. Because of the voluntary participation of the centres and the length of the study it has been impossible to recruit a group of centres from other areas or regions acting as a control group. In relation to the validity of collected data, studies of quality improvement are based on the principle that all unregistered activity is considered not being made. Taking into account the overloaded conditions of working in primary care it can be assumed that health professionals were not able to perform a comprehensive record of the activities, especially in educational issues. In the study period, the computerised medical record was generalised throughout primary care in Catalonia from 2003 to 2004, therefore almost all the medical records reviewed until 2002 were handwritten. In contrast, in the 2007 assessment results were collected from electronic medical records, which may explain the increased number of visits or foot examinations registered in the last assessment. However, no improvements in funduscopy examination or nephropathy screening were observed. As for any study of continuous quality improvement programme, it should not be ruled out that the observed improvements are merely a reflection of an upgrading in medical record registration ([@b23],[@b28]). However, some studies suggest that improvements in electronic management system are not always accompanied by improvements in health outcomes ([@b20]).

Another possible limitation of the study is that participation was voluntary, therefore it could be hypothesised that only more motivated centres for diabetes control participated in the assessments. However, the fact that the health provider responsible for data reviewing was motivated did not preclude that the remaining professionals of the PCC were motivated for diabetes management.

Finally, we must raise the question of whether improvement in process indicators involves improvements in health outcomes indicators. Most interventions show an improvement of the process indicators and intermediate outcomes ([@b21]--[@b23],[@b28]). The comprehensive registration of activities does not guarantee a strict clinical attitude and therefore treatment modification or intensification could not be associated with achievement of treatment goals. However, there is consensus that process indicators are the only tools to monitor the impact of quality interventions because final outcome indicators are neither considered sensitive nor specific as quality of care measures ([@b28]).

It can be concluded that during the study period there have been improvements in the registry of health activities as well as performance of physical examinations and laboratory tests. The improvements achieved in glycemic control and other risk factors may have contributed to the reduction in foot amputations and diabetic retinopathy observed. Although those changes should not be attributed strictly to the GCQI programme, they reflect an improvement in the health of type 2 DM patients managed in primary care in our country.
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